Latest news with #ProlyteORS
News18
29-07-2025
- Health
- News18
Not Hot Enough For ORS, Pharma Companies Left With Surplus Stock Owing To Early Monsoon
Last Updated: Industry insiders said pharmaceutical companies had anticipated a scorching summer and ramped up production of ORS and placed orders A milder-than-usual summer coupled with an early arrival of the monsoon have dented the seasonal demand for ORS in India, leaving several pharmaceutical companies with surplus stock of the vital formula. According to industry insiders, pharma companies had anticipated a scorching summer and ramped up production of oral rehydration salts (ORS) and placed orders. In fact, data from Pharmarac shows the season began on a high note — April recorded sales of Rs 146 crore, an increase from Rs 139 crore in the same month last year, raising expectations for a robust season. But the momentum faded as temperatures stayed moderate and the monsoon arrived ahead of schedule. Weather experts said summer this year lacked the intensity of previous years. Heatwave days were fewer and scattered, and May witnessed relatively cooler spells across several regions. While temperatures briefly rose in June, an early monsoon cut the hot season short. ORS products, which are widely used to prevent dehydration during extreme heat and diarrhoeal illnesses, usually witness a surge in demand during harsh summers. This year, however, has left many manufacturers with unexpected stockpiles. 'Healwood, the largest third-party contract manufacturer that produces ORS for top pharmaceutical companies such as Cipla, Lupin, Alkem, Mankind, Sun and others, is left with large volumes of unsold stock made on order for these companies. This is mainly because of the short summers and early monsoon," Jeswal said. He added: 'The orders included various flavours like lime, jeera, nimbu pani, pineapple, black currant, mixed fruit, etc, but orange and apple remained the most in demand. Most of the other flavours did not sell well." As a result, he said, the cost has not been recovered from the market and companies are now trying to use unsold stock through promotional activities. Carrying stocks for the next year is a loss-making proposition and a burden on profits, as the expiry is just 18 months, he added. 'Companies prepare their orders for the full season in advance as per anticipation because manufacturers are fewer and they are pre-booked," he said. Apart from Jeswal, distributors said many pharma firms are offering their excess inventory for free as part of public outreach and CSR-linked drives. A Cipla distributor in north India, for example, has been distributing Prolyte ORS packs 'for free" at sports and public welfare events to clear backlogged stock. Deepak Arora, vice president of sales and marketing at Wallace Pharmaceuticals — maker of the Rs 100 crore ORS brand Walyte — acknowledged that while his company performed 'fairly okay" this summer, 'a shortened or non-existent summer" contributed to lower-than-expected demand across the market. Despite the seasonal dip, the overall oral electrolyte market continues to grow reaching Rs 1,232 crore in the financial year 2024-2025. ORS works by re-energising the body, relieving dehydration and fatigue, restoring body fluids and minerals, apart from refilling the body with electrolytes during vomiting, loose motions, or dehydration. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
The Wire
01-07-2025
- Health
- The Wire
Cipla Health reinforces importance of Self-Care This Season Through Its Range of Wellness Products
With a rise in COVID cases and seasonal flu, Cipla Health's trusted portfolio empowers everyday health decisions for Indian families MUMBAI, India, July 1, 2025 /PRNewswire/ -- Common flu, seasonal throat infections, and fevers are on the rise in India, making it imperative to practice every day self-care and community protection. Leading the charge, Cipla Health Ltd., one of India's most trusted fast-moving wellness goods (FMWG) companies, through its thoughtful and medically backed range of products, offers holistic support to navigate the ongoing seasonal challenges that have also seen a resurgence in respiratory illnesses like COVID-19. Cipla Health's house of brands, including Cofsils, Cipladine, Prolyte ORS, Paracip, and Maxirich offers reliable solutions for Indian households to better manage these symptoms and maintain wellness. • Cofsils Lozenges offer fast relief from sore throat pain—starting in just 5 minutes. With a triple-action formula that fights viruses, bacteria and soothing effects, they're a handy companion when you're out and about. • Cipladine Gargles target throat infections right at the source. With povidone-iodine, a trusted ingredient for throat hygiene, it soothes symptoms like sore throat and tonsillitis and helps reduce the spread of viruses. It's also effective for on-demand oral care during seasonal illness. • Prolyte ORS is the go-to rehydration solution when one is feeling drained from fever or illness. Its WHO-recommended formula helps restore lost fluids and electrolytes, so they can bounce back quicker and stay balanced. • Paracip is Cipla Health's reliable paracetamol that helps ease common seasonal discomforts like body aches, headaches, and chills • Maxirich Daily Multivitamin helps keeping the energy up and immunity strong. Packed with over 13 essential vitamins and minerals, it supports everyone's daily health needs. Commenting on this, Mr. Shivam Puri, MD & CEO, Cipla Health Limited, said, "At Cipla Health, our focus is to bring dependable preventive wellness solutions to every Indian household. With the weather shifting and instances of seasonal flu, respiratory illnesses on the rise, it is imperative to have access to simple yet effective care solutions. Our product portfolio has been thoughtfully designed to support families in staying prepared and protected." By offering solutions rooted in science, Cipla Health continues to fulfil its mission of making wellness accessible, proactive, and holistic for all. Whether it's the common seasonal flu or an unseen viral wave, being prepared with the right care tools can go a long way in staying safe. About Cipla Health Limited: Cipla Health Limited, the fast-moving wellness goods (FMWG) arm of Cipla, was incorporated in 2015 with a vision to spearhead the wellness wave in India. Cipla Health has delivered rapid growth and today plays across a diverse portfolio of 20 brands with most key brands being No. 1 or No. 2 in their respective categories. The portfolio includes products in Pain Care (Omnigel), Smoking Cessation (Nicotex), Oral Rehydration Solutions (Prolyte), Medicated Ointments (Cipladine), Cough & Cold (Cofsils and Naselin), Multi Vitamins (Maxirich), Weight Gain (Endura Mass) and Personal Care (Rivela Dermascience, Cetafresh, Tugain Essentials). Logo: (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.).
Business Standard
01-07-2025
- Health
- Business Standard
Cipla Health reinforces importance of Self-Care This Season Through Its Range of Wellness Products
PRNewswire Mumbai (Maharashtra) [India], July 1: Common flu, seasonal throat infections, and fevers are on the rise in India, making it imperative to practice every day self-care and community protection. Leading the charge, Cipla Health Ltd., one of India's most trusted fast-moving wellness goods (FMWG) companies, through its thoughtful and medically backed range of products, offers holistic support to navigate the ongoing seasonal challenges that have also seen a resurgence in respiratory illnesses like COVID-19. * With a rise in COVID cases and seasonal flu, Cipla Health's trusted portfolio empowers everyday health decisions for Indian families Cipla Health's house of brands, including Cofsils, Cipladine, Prolyte ORS, Paracip, and Maxirich offers reliable solutions for Indian households to better manage these symptoms and maintain wellness. * Cofsils Lozenges offer fast relief from sore throat pain--starting in just 5 minutes. With a triple-action formula that fights viruses, bacteria and soothing effects, they're a handy companion when you're out and about. * Cipladine Gargles target throat infections right at the source. With povidone-iodine, a trusted ingredient for throat hygiene, it soothes symptoms like sore throat and tonsillitis and helps reduce the spread of viruses. It's also effective for on-demand oral care during seasonal illness. * Prolyte ORS is the go-to rehydration solution when one is feeling drained from fever or illness. Its WHO-recommended formula helps restore lost fluids and electrolytes, so they can bounce back quicker and stay balanced. * Paracip is Cipla Health's reliable paracetamol that helps ease common seasonal discomforts like body aches, headaches, and chills * Maxirich Daily Multivitamin helps keeping the energy up and immunity strong. Packed with over 13 essential vitamins and minerals, it supports everyone's daily health needs. Commenting on this, Mr. Shivam Puri, MD & CEO, Cipla Health Limited, said, "At Cipla Health, our focus is to bring dependable preventive wellness solutions to every Indian household. With the weather shifting and instances of seasonal flu, respiratory illnesses on the rise, it is imperative to have access to simple yet effective care solutions. Our product portfolio has been thoughtfully designed to support families in staying prepared and protected." By offering solutions rooted in science, Cipla Health continues to fulfil its mission of making wellness accessible, proactive, and holistic for all. Whether it's the common seasonal flu or an unseen viral wave, being prepared with the right care tools can go a long way in staying safe. About Cipla Health Limited: Cipla Health Limited, the fast-moving wellness goods (FMWG) arm of Cipla, was incorporated in 2015 with a vision to spearhead the wellness wave in India. Cipla Health has delivered rapid growth and today plays across a diverse portfolio of 20 brands with most key brands being No. 1 or No. 2 in their respective categories. The portfolio includes products in Pain Care (Omnigel), Smoking Cessation (Nicotex), Oral Rehydration Solutions (Prolyte), Medicated Ointments (Cipladine), Cough & Cold (Cofsils and Naselin), Multi Vitamins (Maxirich), Weight Gain (Endura Mass) and Personal Care (Rivela Dermascience, Cetafresh, Tugain Essentials).
